Sensars develops implantable neuroprosthetic and neurostimulation systems designed to restore protective sensation in people with diabetic neuropathy and limb loss. Its SENSY platform combines nerve-implanted electrodes with smart wearable insoles, and preliminary human trials have demonstrated sensory restoration, improved gait and reduced pain. The Swiss-founded company’s work has appeared in more than 25 peer-reviewed publications and received FDA Breakthrough Device Designation.
FDA Breakthrough Device Designation
compliance_program
D.SoleD.Sole is a Pittsburgh health-technology company built around expertise in biomedical engineering, robotics, artificial intelligence, and podiatry. It develops wearable monitoring insoles for people with diabetes, using machine learning to help clinicians spot developing foot complications early.PITTSBURGH, PA
Sharper SenseSharper Sense develops single-use neurostimulation patches worn on the neck to enhance cognition and sensory processing. Its hands-free, maintenance-free patch uses a noninvasive electric field to stimulate cervical nerves, with research on the approach appearing in Nature Scientific Reports and other neuroscience publications. The company is applying the technology to situations where fatigue and distraction can increase human error, including military, sports, first-response and shift-work settings.NEW YORK, NY
Renerva, IncFounded in 2017 out of the University of Pittsburgh and Cornell University, Pittsburgh-based Renerva develops implantable medical devices and biomaterials for peripheral nerve injury, including its investigational PNM-CAP nerve-capping device for neuroma pain. The company’s research centers on decellularized porcine nerve extracellular matrix, with products intended to help limit painful nerve growth or support nerve recovery; its technologies are not yet commercially available. Renerva operates from Pittsburgh with a satellite location in Ithaca, New York.PITTSBURGH, PA
SenseonicsGermantown-based Senseonics develops and commercializes Eversense, an implantable continuous glucose monitoring system designed to provide real-time diabetes data through a sensor placed under the skin. Its Eversense 365 system is designed to last for up to one year, with a removable, rechargeable smart transmitter and mobile app for glucose tracking. Senseonics describes Eversense as the first and only long-term implantable CGM platform.GERMANTOWN, MD